Volume 55, Issue 2, Pages (February 1999)

Slides:

Advertisements

Similar presentations

Renal disease and hypertension in non–insulin-dependent diabetes mellitus Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz Kidney International.

Advertisements

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Volume 91, Issue 3, Pages (March 2017)

Cyril H. Barton, Zehnmin Ni, Nosratola D. Vaziri Kidney International

Sodium thiosulfate prevents vascular calcifications in uremic rats

Volume 67, Issue 6, Pages (June 2005)

Volume 61, Issue 4, Pages (April 2002)

Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali.

Volume 67, Issue 2, Pages (February 2005)

Volume 61, Issue 2, (February 2002)

Volume 55, Issue 5, Pages (May 1999)

Volume 58, Issue 6, Pages (December 2000)

Volume 77, Issue 1, Pages 6-8 (January 2010)

Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes Lesley Wassef, Darren J. Kelly, Richard E. Gilbert

Volume 59, Issue 4, Pages (April 2001)

Left ventricular hypertrophy in renal failure

Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Volume 54, Issue 5, Pages (November 1998)

Volume 57, Issue 5, Pages (May 2000)

Isotretinoin alleviates renal damage in rat chronic glomerulonephritis

Volume 63, Issue 5, Pages (May 2003)

Calcification and cardiovascular problems in renal failure

Volume 87, Issue 2, Pages (February 2015)

Enlightenment on liver lanthanum exposure

Volume 58, Issue 6, Pages (December 2000)

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Metabolic acidosis inhibits soft tissue calcification in uremic rats

Volume 74, Issue 10, Pages (November 2008)

E. Neven, S. Dauwe, M.E. De Broe, P.C. D'Haese, V. Persy

Ferruh Artunc, Friedhelm Hildebrandt, Kerstin Amann

Volume 60, Issue 4, Pages (October 2001)

Role of vitamin D receptor activators on cardiovascular risk

Volume 75, Issue 1, Pages (January 2009)

Volume 67, Issue 2, Pages (February 2005)

New insights in uremic toxins

The third World Kidney Day: Looking back and thinking forward

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

Calcium sensing in podocytes

Volume 65, Issue 6, Pages (June 2004)

Volume 79, Issue 9, Pages (May 2011)

Counteracting progression of renal disease: A look into the future

Nephrology Crossword: Glomerulonephritis

Citrate therapy for polycystic kidney disease in rats

Volume 71, Issue 4, Pages (February 2007)

Volume 71, Issue 3, Pages (February 2007)

Volume 62, Issue 3, Pages (September 2002)

Volume 78, Issue 8, Pages (October 2010)

Leptin and inflammation-associated cachexia in chronic kidney disease

The course of the remnant kidney model in mice

Phosphate binders on iron basis: A new perspective?

Organ transplantation goes to the movies

The vascular secret of Klotho

Volume 58, Issue 4, Pages (October 2000)

Volume 72, Issue 3, Pages (August 2007)

Sandrine Billet, Fréderick Aguilar, Camille Baudry, Eric Clauser

Volume 81, Issue 2, Pages (January 2012)

Volume 75, Issue 7, Pages (April 2009)

Vasopressin antagonists in polycystic kidney disease

Ralf Dikow, Marcin Adamczak, Daniel Ernesto Henriquez, Eberhard Ritz

Volume 62, Issue 3, Pages (September 2002)

Volume 61, Issue 6, Pages (June 2002)

Volume 75, Issue 8, Pages (April 2009)

Volume 53, Issue 6, Pages (June 1998)

Morphology of the heart and arteries in renal failure

Volume 55, Issue 2, Pages (February 1999)

Presentation transcript:

Volume 55, Issue 2, Pages 512-519 (February 1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats Alexander V. Nabokov, Kerstin Amann, Sabine Wessels, Klaus Münter, Jürgen Wagner, Eberhard Ritz Kidney International Volume 55, Issue 2, Pages 512-519 (February 1999) DOI: 10.1046/j.1523-1755.1999.00290.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Structural changes of the myocardium in subtotally nephrectomized (SNx) rats eight weeks after the start of the experiment. Representative findings in sham-operated (A), untreated SNx (B), BMS182874-treated SNx (C), and Ro46-2005-treated SNx animals (D). These figures illustrate the increase of interstitial tissue in the untreated SNx animal with the most prominent interstitial expansion (B) and the absence of intramyocardial interstitial enlargement in sham (A) and both groups receiving the ET receptor antagonists (C and D). Semithin section, methylene blue—basic fuchsin (magnification A, C, and D ×640; B, ×1100). Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Structural changes of small intramyocardial arteries in SNx rats eight weeks after the start of the experiment. Representative arteriolar sections of sham-operated (A), untreated SNx (B), trandolapril-treated SNx (C), and BMS182874-treated SNx animals (D). The arteriolar wall thickness is considerably greater in SNx (B) than in sham operated animals (A) and animals of the two treated SNx groups (C and D). Semithin section, methylene blue–basic fuchsin (magnification ×640). Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Structural changes of the aorta in SNx rats eight weeks after the start of the experiment. Representative sections of the aortic wall of sham-operated (A), untreated SNx (B), trandolapril-treated SNx (C), BMS182874-treated SNx (D), and Ro46-2005–treated SNx animals (E). An increase in media thickness is observed in untreated SNx animals (B). Such an increase is attenuated in SNx animals treated with trandolapril (C), but not in SNx animals treated with either ET receptor antagonist (D and E). Semithin sections, methylene blue–basic fuchsin (magnification ×320). Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Kidney International 1999 55, 512-519DOI: (10. 1046/j. 1523-1755. 1999 Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Kidney International 1999 55, 512-519DOI: (10. 1046/j. 1523-1755. 1999 Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Kidney International 1999 55, 512-519DOI: (10. 1046/j. 1523-1755. 1999 Kidney International 1999 55, 512-519DOI: (10.1046/j.1523-1755.1999.00290.x) Copyright © 1999 International Society of Nephrology Terms and Conditions